Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI356 in Moderate to Severe Atopic Dermatitis
NCT07330934Phase 2Terminated
- Sponsor
- Innovent Biologics
- Start
- Dec 2025
- Primary completion
- Aug 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of IBI356 in atopic dermatitis (AD), sponsored by Innovent Biologics. Started Dec 2025; status: terminated.
02
Drugs
IBI356
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07330934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07330934.